The method of treatment of malignant tumors

 

(57) Abstract:

The invention relates to medicine, namely to Oncology, and can be used for the treatment of patients with locally advanced cancer process. To do this, take 700 - 1000 ml of lymph from the thoracic duct, centrifuged, removing the plasma from tumor cells. The obtained suspension is incubated with exchange doses of chemotherapy drugs and injected into the regional artery supplying the organ affected by the tumor. The method leads to the reduction of the tumor until its complete disappearance in the translation inoperable patients in operable condition. The method is devoid of side effects, prolongs the duration of recurrence-free period and prolong the survival of patients. The effectiveness of the method is especially valuable when irresectable tumors. 1 of Fig.

The invention relates to medicine, namely to Oncology and can be used for the treatment of patients with locally advanced cancer process.

There is a method of treatment of malignant tumors intra-arterial infusion chemotherapy (see kN. C. A. Gasparyan, H. E. Ostroverkhov, N. N. Trapeznikov "Regional long-term intra-arterial chemotherapy of malignant tumor is defined tumor body with introduction through the catheter chemotherapy, that provides direct contact of chemicals with tumor cells. The disadvantage of this method is the impossibility high doses of chemotherapy drugs because of adverse complications.

There is a method of treatment of malignant tumors by autolithography (see Art. "Autolymphocyte in the treatment of lung cancer", Ed. Ilovesnow Century, Cervina E. D. Zverev, Y. N. (Proceedings of the I Congress of oncologists of the Republic of Uzbekistan with international participation" June 28-30, 1994, page 74), lies in the catheterization thoracic duct, intake lymph, dissolving in it the maximum doses of chemotherapy and subsequent intravenous.

The disadvantage of this method of treatment of malignant tumors is getting autolamp with chemotherapy in the overall flow, resulting in chemotherapy undergo neutralization physiological antidotes, as well as delivery to the tumor growth is only part of the injected doses of chemotherapy.

The aim of the invention is to improve the treatment efficacy while reducing side effects.

This objective is achieved in that according to a known method, drain the breast lymphatics is with tumor cells, the obtained suspension is incubated with the maximum tolerated dose chemotherapy and conduct intra-arterial chemotherapy is injected into a regional artery supplying the organ affected by the tumor.

The invention is new, as is not known from the level of medicine in the field of regional long-term intra-arterial chemotherapy of malignant tumors using autolamp, when treating patients with locally advanced cancer process. The novelty of the proposed technical solutions - "method of treatment of malignant tumors is that of the removed lymph plasma containing tumor cells, the remaining suspension is mixed with directional dose chemotherapy and through the introduction of a regional vessel is fed directly to the tumor.

The invention involves an inventive step, as for a specialist oncologist is not obvious from the level of development of medicine, in particular cancer, in the treatment of patients with locally advanced cancer process. On the proposed "Method of treatment of malignant tumors using spin-on lymph, incubated with chemotherapy drugs in the course number of doses supplied napora, the maximum tolerated doses of chemotherapeutic drugs, without side effects on the body.

Therefore, the proposed solution may not be obvious and follows from the level of development in this field of Oncology, as it is not known neither in the world nor in the Russian (CIS) medical literature.

The invention is industrially applicable as it can be used in health care: hospitals, breast care clinics, Oncology research Institute, in the treatment of patients with mestnorasprostranenny cancer process and it is particularly valuable in Oncology, the treatment of unresectable.

The essence of the method is confirmed by the drawing, which shows:

1. The cancer that affects the left half of the tongue, mouth and body of the mandible.

2. The external carotid artery.

3. The internal carotid artery.

4. Catheterized lingual artery.

5. Common carotid artery.

6. The internal jugular vein.

7. Catheterized thoracic duct.

8. Left nameless Vienna.

9. Vial (capacity) for sampling lymph.

10. Arch of the aorta.

A method of treating malignant Oprea, nourishing the body is affected by the tumor. Allocated trunk thoracic duct, which drains and connects with a sterile vial with a capacity of 200-250 ml where Universiada liquid (solution "Gleyzer"). Performs intake of 800-1000 ml of lymph in four capsules. The end of the catheter is closed. Ampoules with lymph centrifugeuse to obtain plasma and suspended solids. The pipette is extracted from the plasma, and the remaining suspension is injected dose rate of chemotherapy, dividing it into 4 parts 1 part in each ampoule. Incubation is carried out for 30 min at a temperature of 37oC. the Prepared solution is injected by syringe under pressure in a regional artery for 10-15 minutes.

The invention is illustrated by the following example 1. Patient STO. b-nor 3041 N/A was admitted with a diagnosis of common oral cancer with metastasis to the submandibular lymph nodes. Complaints received at a severe headache and oral pain, difficulty eating. When viewed in the left half of the mouth ulcerated tumor process with distribution, on the left half of the tongue, retromolar region, the lining of the alveoli of the mandible, associated with a fixed submandibular lymph nodes. Because of the high prevalence of process case preter, introduced into the artery, sealed thermal way. After filling four vials of 250 ml each of lymphatic fluid, which took 12 hours, ampoules centrifuged. Removed plasma. In the left volume 125 ml suspension in each ampoule put on 35 mg of methotrexate and 500 mg of cyclophosphamide. The contents of each ampoule is introduced into the lingual artery syringe under pressure for 15 minutes. Just put 500 ml of lymph suspension of 150 mg of methotrexate and 2 g of platinum. The manipulation was performed 4 times: twice a week for 2 weeks. On the 20th day of tumor process in the oral cavity was reduced by more than 50%. Lymph nodes decreased and became mobile. Overall condition has improved. Headache is gone, pain in the oral cavity decreased significantly. The patient has ceased to apply pain-relieving drugs. The meal was painless. With the downsizing of the tumor process, he became resectable. Blood and urine without significant changes. On the 30th day from the beginning of regional autolymphochemotherapy produced radical surgery - removal of the tumor oropharyngeal region, the upper fasciale-casing neck excision. In view of intactness lower jaw, last saved. Paleoposition is giving 5 months without relapse. Swallowing a natural way. It saved.

The technical result from the use of the "method of treatment of malignant tumors is to improve the immediate treatment results in decreased tumor and translation inoperable patients in operable condition, while reducing side effects. Longer term relapse-free period and increases the duration of survival of patients. The effectiveness of the method is especially valuable when irresectable tumors.

The method of treatment of malignant tumors, including intra-arterial regional chemotherapy, characterized in that the take 700 - 1000 ml of lymph from the thoracic duct, centrifuged, removing the plasma from tumor cells obtained suspension is incubated with chemotherapy drugs in the course doses and injected into the regional artery supplying the organ affected by the tumor.

 

Same patents:
The invention relates to medicine, namely and gynecology, and can be used with chemotherapy ascitic ovarian cancer III-IV stages)
The invention relates to medicine, gynecology
The invention relates to medicine, namely to addiction
The invention relates to medicine, namely to methods of treatment of patients with infectious and septic diseases with secondary immunodeficiency
The invention relates to medicine, namely to addiction
The invention relates to veterinary medicine
The invention relates to medicine, in particular to the treatment of chronic inflammatory diseases
The invention relates to medicine, in particular to Oncology and concerns immune for complex treatment of tumors

The invention relates to medicine, in particular immunology, and can be used for the prevention and treatment of immunodeficiency States
The invention relates to ophthalmology
The invention relates to medicine, namely to urology, and can be used in the treatment of prostatitis
The invention relates to medicine, namely and gynecology, and can be used with chemotherapy ascitic ovarian cancer III-IV stages)
The invention relates to medicine, namely to experimental Oncology, and can be used to reduce toxicity and enhance the antitumor activity of cyclophosphamide
The invention relates to medicine, namely to Oncology, and for the treatment of patients with nodular forms of breast cancer
The invention relates to medicine, namely to traumatology and can be used in the damage of skeletal muscles
The invention relates to medicine, namely to cancer and for the treatment of patients with diffuse forms of breast cancer
The invention relates to medicine, namely to Oncology, and for chemotherapy of disseminated breast cancer

FIELD: medicine, ophthalmology.

SUBSTANCE: one should apply an autohemocomponent preparation being supernatant liquid of patient's autoblood at increased serotonin content obtained due to irreversible thrombocytic aggregation due to the impact of 0.5 mg ATP per 1.0 ml plasma followed by a 30-min-long centrifuging at the rate of 1000, 2000 and 3000 rot./min for 20, 7 and 3 min, correspondingly. In case of no exudative phenomena on patient's eye bottom the obtained preparation should introduced at the quantity of 7-10 ml once in 48 h for 1 mo (totally, 15 injections). In case of exudative-hemorrhagic phenomena it should be introduced parabulbarly at the volume of 0.5 ml and parenterally - 7.0-10.0 ml once in 48 h for 1 mo per 15 injections, correspondingly. The preparation enables to improve visual functions due to decreased tissue hypoxia and normalization of microcirculation in visual analyzer.

EFFECT: higher efficiency of therapy.

2 cl, 7 dwg, 2 ex

Up!